TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15471004

Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 107
Study: 11471776

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 18
Study: 9489589

Group type: COMPARATOR
Intervention: Marimastat 25, 50, 100, 200, 400, and 800 mg single doses
Number of subjects: 31

Group type: COMPARATOR
Intervention: Marimastat 50, 100, and 200 mg twice daily for 6.5 days
Number of subjects: 31
Study: 7817726

Group type: EXPERIMENTAL
Intervention: Hyperemesis gravidarum patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control subjects (23 subjects of comparable gestational age)
Number of subjects: 39
Study: 3398127

Group type: EXPERIMENTAL
Intervention: Postoperative course of oral antibiotics (group 2)
Number of subjects: 138

Group type: COMPARATOR
Intervention: No antibiotic (controls, group 1)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Overall incidence
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Symptomatic infection
Number of subjects: 138
Study: 31680604

Group type: EXPERIMENTAL
Intervention: Omega-3/Omega-6 fatty acids
Number of subjects: 40
Study: 29190847

Group type: EXPERIMENTAL
Intervention: Indicated preterm birth (IPTB)
Number of subjects: 9867

Group type: COMPARATOR
Intervention: Spontaneous preterm birth (SPTB)
Number of subjects: 9867
Study: 26968359

Group type: EXPERIMENTAL
Intervention: Hypofractionation (19 fractions of 3.4 Gy in 6.5 weeks)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Standard fractionation (39 fractions of 2 Gy in 8 weeks)
Number of subjects: 820
Study: 25896635

Group type: EXPERIMENTAL
Intervention: IVIG at 0.5 g/kg per week
Number of subjects: 23

Group type: COMPARATOR
Intervention: IVIG at 1 g/kg per week
Number of subjects: 23
Study: 23605883

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: Bevacizumab 5 mg/kg every 2 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily plus bevacizumab 2 mg/kg every 2 weeks
Number of subjects: 126
Study: 20529983

Group type: EXPERIMENTAL
Intervention: 60 mg hyperbaric 2% prilocaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 40 mg hyperbaric 2% prilocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 60 mg plain 2% prilocaine
Number of subjects: 90
Study: 18379200

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (Montelukast and Placebo)
Number of subjects: 50
Study: 16603098

Group type: EXPERIMENTAL
Intervention: Clotrimazole (antimycotic agent)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Yeast infected but not treated patients
Number of subjects: 126

Group type: COMPARATOR
Intervention: Yeast-free controls
Number of subjects: 126
Study: 12909511

Group type: EXPERIMENTAL
Intervention: Application of autocrosslinked hyaluronic acid (HA) gel (group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No application of autocrosslinked hyaluronic acid (HA) gel (group B)
Number of subjects: 36
Study: 9520227

Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg q.i.d.)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg q.i.d.) plus Codeine (40 mg q.i.d.)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg q.i.d.) plus Imipramine (10 or 25 mg t.i.d.)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo plus Diclofenac (50 mg q.i.d.)
Number of subjects: 184
Study: 7924321

Group type: EXPERIMENTAL
Intervention: Progestogen-only contraceptives (pill, DMPA, NET-EN, NORPLANT implants)
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Non-hormonal methods (IUD, barrier methods, sterilization)
Number of subjects: 2466
Study: 2622580

Group type: EXPERIMENTAL
Intervention: Ofloxacin 600 mg/day for 3 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg/day for 3 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ofloxacin 600 mg/day for 5 days
Number of subjects: 45
Study: 1091029

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of adenine infused intravenously over one hour
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of adenine infused intravenously over one hour
Number of subjects: 8

Group type: COMPARATOR
Intervention: No adenine (control group)
Number of subjects: 8
Study: 31773200

Group type: EXPERIMENTAL
Intervention: 3-month exercise programme for reducing abdominal fat (PRAF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 30024294

Group type: EXPERIMENTAL
Intervention: High loneliness induction
Number of subjects: 97

Group type: COMPARATOR
Intervention: Low loneliness induction
Number of subjects: 97
Study: 28606267

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate eye drop (Group B)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lipid‐containing carbomer gel (Group C)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional antibiotics (Group A)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate eye drop (Group B) and Lipid‐containing carbomer gel (Group C)
Number of subjects: 102
Study: 23811112

Group type: EXPERIMENTAL
Intervention: Danoprevir 300 mg every 8 hours
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Danoprevir 600 mg every 12 hours
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Danoprevir 900 mg every 12 hours
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 20643862

Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 214

Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 214
Study: 19586701

Group type: EXPERIMENTAL
Intervention: EZ-IO
Number of subjects: 29

Group type: COMPARATOR
Intervention: BIG
Number of subjects: 29
Study: 17432638

Group type: EXPERIMENTAL
Intervention: Eye-needling combined with medication
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medication (control group)
Number of subjects: 120
Study: 15361698

Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 11401920

Group type: EXPERIMENTAL
Intervention: Cytobrush samples (n = 120)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mouthwash samples (n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cytobrush samples (n = 28) in phase 2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mouthwash samples (n = 25) in phase 2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mouthwash extracts
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cytobrush extracts
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cytobrush and mouthwash phenol‐chloroform extracts
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NaOH extracted DNA from cytobrush samples
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mouthwash or cytobrush samples
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Single mouthwash sample
Number of subjects: 120
Study: 10069757

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-molecular-weight heparin (LMWH), tinzaparin sodium, once-daily dose.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous heparin therapy, initial continuous intravenous infusion followed by 3 months of warfarin therapy.
Number of subjects: 200
Study: 7992418

Group type: EXPERIMENTAL
Intervention: Incision, curettage and primary suture under antibiotic cover
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional, 'open' treatment
Number of subjects: 17
Study: 1969068

Group type: EXPERIMENTAL
Intervention: Selective decontamination (test group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional perioperative antibiotic prophylaxis (controls)
Number of subjects: 114
Study: 665

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31852712

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1500 mg), thiamine (100 mg), hydrocortisone (50 mg) every 6 hours for 4 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo every 6 hours for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ascorbic acid, corticosteroids and thiamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28549298

Group type: EXPERIMENTAL
Intervention: Late-night dinner at 2100h (D21)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Divided dinner (vegetable and rice at 1800h and main dish at 2100h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dinner at 1800h (D18)
Number of subjects: 16
Study: 26036543

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 67
Study: 24165049

Group type: EXPERIMENTAL
Intervention: Peripheral nerve adjustment (group B)
Number of subjects: 102
Study: 21543951

Group type: EXPERIMENTAL
Intervention: Dual-focus schema therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Individual drug counseling
Number of subjects: 105
Study: 19428879

Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine (11PCV)
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111
Study: 16457000

Group type: EXPERIMENTAL
Intervention: Follow-up infected group (FU-I)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Follow-up noninfected group (FU-NI)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 195
Study: 16510656

Group type: EXPERIMENTAL
Intervention: Behavioral assessment using Conners' Parent Rating Scale
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Wechsler Intelligence Scale for Children-III
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: CD4 lymphocyte count correlation
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Age correlation with anxiety problems
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Neuroimaging correlation
Number of subjects: 274
Study: 12732767

Group type: EXPERIMENTAL
Intervention: Early second-look laparoscopy (SLL) with adhesiolysis in 46 women (group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No second-look laparoscopy in 44 women (group 2)
Number of subjects: 90
Study: 10361108

Group type: COMPARATOR
Intervention: TAD (standard-dose cytarabine with daunorubicin and 6-thioguanine)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: TAD-HAM (high-dose cytarabine with mitoxantrone)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: TAD-HAM (high-dose cytarabine with mitoxantrone) in poor prognosis subgroup
Number of subjects: 725

Group type: COMPARATOR
Intervention: TAD (standard-dose cytarabine with daunorubicin and 6-thioguanine) in poor prognosis subgroup
Number of subjects: 725
Study: 7676504

Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of CsA, 400 mg oral dose
Number of subjects: 11

Group type: COMPARATOR
Intervention: Currently marketed formulation of CsA, 400 mg oral dose
Number of subjects: 11
Study: 2155476

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid, carprofen, diclofenac, indomethacin, naproxen, proquazone, timegadine, tolfenamic acid, paracetamol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 53
Study: 112265

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31719078

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) route - 8 infusions over 4 days, then again for 4 days in week 4 (total of 240 g of stool)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Colonoscopic infusion followed by seven weekly enemas (total of 360 g of stool)
Number of subjects: 30
Study: 28263734

Group type: COMPARATOR
Intervention: IOL Master 500
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pentacam AXL
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 79
Study: 26209856

Group type: EXPERIMENTAL
Intervention: Single intraoperative dose of dexamethasone
Number of subjects: 734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study: 23537954

Group type: EXPERIMENTAL
Intervention: CABG SXscore
Number of subjects: 115

Group type: COMPARATOR
Intervention: Low CABG SXscore group
Number of subjects: 115
Study: 22132755

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment at 4 acupuncture points, ST23 and ST27, bilaterally, 3 times per week for four weeks.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham moxibustion treatment at 4 acupuncture points, ST23 and ST27, bilaterally, 3 times per week for four weeks.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment
Number of subjects: 26
Study: 19421690

Group type: EXPERIMENTAL
Intervention: Intervention hospital
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control hospital
Number of subjects: 641
Study: 17087245

Group type: EXPERIMENTAL
Intervention: Clexane, 40 mg, administered 12 hours before and within 7-18 days after surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonspecific prevention of thrombotic events
Number of subjects: 80
Study: 15021224

Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridoplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary Lens Extraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ocular Hypertension (OH) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-risk OH and Primary Open Angle Glaucoma (POAG) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latanoprost and Brimonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trabeculectomy combined with Blumenthal technique
Number of subjects: 0
Study: 11182670

Group type: EXPERIMENTAL
Intervention: Augmented surgery (group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Prism adaptation (group P)
Number of subjects: 43
Study: 9286520

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 0.25 mg F as NaF for 5, 10, 15, 20, 30, or 45 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-chewing side
Number of subjects: 10
Study: 12959292

Group type: EXPERIMENTAL
Intervention: Modified metered‐dose actuator device (MA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard metered‐dose inhaler (MDI)
Number of subjects: 10
Study: 3526720

Group type: EXPERIMENTAL
Intervention: Eleutherococcus extract
Number of subjects: 0
Study: 31096498

Group type: EXPERIMENTAL
Intervention: Oral carbohydrate solution 710 mL the night before and 355 mL 2 hours prior to operation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Fasting for 10 hours prior to operation
Number of subjects: 73
Study: 28603100

Group type: EXPERIMENTAL
Intervention: Total closure of pancreatic section for end‐to‐side pancreaticojejunostomy (Group A)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional pancreaticojejunostomy (Group B)
Number of subjects: 123
Study: 25921843

Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 38
Study: 23032410

Group type: EXPERIMENTAL
Intervention: Monotherapy with ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Continued therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Alzheimer dementia
Number of subjects: 49
Study: 22046723

Group type: EXPERIMENTAL
Intervention: Clinician's gaze
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Time-based response
Number of subjects: 110
Study: 19067075

Group type: EXPERIMENTAL
Intervention: DJBS
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low fat diet control
Number of subjects: 39
Study: 16957558

Group type: EXPERIMENTAL
Intervention: Methionine 100 mg/kg (study 1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Methionine 200 mg/kg (study 2)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (study 1 and study 2)
Number of subjects: 43
Study: 15354036

Group type: EXPERIMENTAL
Intervention: Glucose infusion (20% in saline; carbohydrate (CHO) at a rate of 1 g x min(‐1))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (0.9% saline; placebo (PLA))
Number of subjects: 6
Study: 12573179

Group type: EXPERIMENTAL
Intervention: Computerized Scheduled Gradual Reduction (CSGR)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Manual-based Selective Elimination Reduction (SER)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups (CSGR and SER)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Subjects with a current desire for smoking cessation
Number of subjects: 93
Study: 9686797

Group type: EXPERIMENTAL
Intervention: Endoscopic harvesting technique (EHT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open harvesting technique (OHT)
Number of subjects: 60
Study: 7978956

Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa) in depot formulation (Zoladex) with transdermal 17‐beta‐estradiol and oral progestin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 2722724

Group type: EXPERIMENTAL
Intervention: Cefmetazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 0
Study: 31702802

Group type: EXPERIMENTAL
Intervention: Bimodal release ondansetron (6 mg immediate release and 18 mg 24-hour release, total 24 mg)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Bimodal release ondansetron
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 28229892

Group type: EXPERIMENTAL
Intervention: Opicinumab (100 mg/kg intravenously once every 4 weeks for six doses)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (intravenously once every 4 weeks for six doses)
Number of subjects: 82
Study: 26608440

Group type: EXPERIMENTAL
Intervention: Empowerment program (MAGIC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 65
Study: 23116775

Group type: EXPERIMENTAL
Intervention: Iron supplementation (ferrous sulfate, 10 mg of elemental iron per day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no iron supplementation)
Number of subjects: 53
Study: 21349218

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg) + Mebendazole (500 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Praziquantel (40 mg/kg) alone
Number of subjects: 82
Study: 19346844

Group type: COMPARATOR
Intervention: Intravenous beta-blocker (landiolol hydrochloride, mean dose of 0.032 mg/kg per minute)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Coadministration of intravenous beta-blocker and sublingual NTG (0.3 mg)
Number of subjects: 60
Study: 16689997

Group type: EXPERIMENTAL
Intervention: Thermographic imaging during temperature provocation (cooling and warming)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Thermographic imaging during static measurement at room temperature
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thermographic imaging during cold and warm temperature challenges
Number of subjects: 12
Study: 15298609

Group type: EXPERIMENTAL
Intervention: Eradication therapy
Number of subjects: 164

Group type: COMPARATOR
Intervention: Non-eradicated group
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Nonsmoking group post-eradication
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Smoking group post-eradication
Number of subjects: 164
Study: 11304056

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg over 48 hours)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Halofantrine (8 mg/kg, 3 doses)
Number of subjects: 54
Study: 8869511

Group type: EXPERIMENTAL
Intervention: Intervention (not specified)
Number of subjects: 617
Study: 1505554

Group type: EXPERIMENTAL
Intervention: Rehabilitation (R) group
Number of subjects: 171

Group type: COMPARATOR
Intervention: Reference, hospital-based treatment (H) group
Number of subjects: 171
Study: 6320360

Group type: EXPERIMENTAL
Intervention: co-trimoxazole
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: pivmecillinam/pivampicillin
Number of subjects: 52
Study: 31604428

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.25μg/kg) added to ropivacaine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.50μg/kg) added to ropivacaine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0μg/kg) added to ropivacaine
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ropivacaine alone (without dexmedetomidine)
Number of subjects: 125
Study: 28772281

Group type: EXPERIMENTAL
Intervention: Linsitinib 150 mg BID plus erlotinib 150 mg QD
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo plus erlotinib 150 mg QD
Number of subjects: 205
Study: 26964164

Group type: EXPERIMENTAL
Intervention: Acupoint application therapy with bushentongyu plaster and tamsulosin hydrochloride (0.2 mg every night for 100 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride (0.2 mg every night for 100 days)
Number of subjects: 50
Study: 23767986

Group type: COMPARATOR
Intervention: 1 mg daily oral rasagiline (monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 mg daily oral rasagiline (adjunct therapy with levodopa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 mg daily oral rasagiline (adjunct therapy)
Number of subjects: 0
Study: 21285525

Group type: EXPERIMENTAL
Intervention: Self-stretching and soft tissue TrP manual therapy (Str-ST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-stretching (Str)
Number of subjects: 60
Study: 19880463

Group type: EXPERIMENTAL
Intervention: Initial treatment with selective serotonin reuptake inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-year treatment continuation
Number of subjects: 0
Study: 16289979

Group type: EXPERIMENTAL
Intervention: DAG meal
Number of subjects: 13

Group type: COMPARATOR
Intervention: TAG meal
Number of subjects: 13
Study: 15851173

Group type: EXPERIMENTAL
Intervention: Biventricular programmed electrical stimulation (BV-PES)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Right ventricular programmed electrical stimulation (RV-PES)
Number of subjects: 18
Study: 11054616

Group type: COMPARATOR
Intervention: Tirofiban
Number of subjects: 4750